Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin-6) in the long-term followup of patients with giant cell arteritis

Arthritis Care and Research

Volumn 62, Issue 6, 2010, Pages 835-841

  García Martínez, Ana ^a   Hernández Rodríguez, José ^a   Espígol Frigolé, Georgina ^a   Prieto González, Sergio ^a   Butjosa, Montserrat ^a   Segarra, Marta ^a   Lozano, Ester ^a   Cid, Maria C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EVALUATION; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RELAPSE; REMISSION; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953087545     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20043     Document Type: Article

References (40)

1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-245
2. Nuenninghoff TJ, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complications (aortic aneurysm, aortic dissection, and/or large artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48:3522-3531
3. Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, Paredes P, Segarra M, Lozano E, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008;59:422-430
4. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R, Lopez-Diaz MJ, Vazquez-Trinanes MC, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009;88:227-235
5. Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villalta J, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis: influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-893 (Pubitemid 19181011)
6. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med 1994;121:484-491
7. Martinez-Taboada VM, Alvarez L, Ruiz Soto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207-220
8. Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004;43:294-301. (Pubitemid 38313176)
9. Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-2434 (Pubitemid 36605224)
10. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant cell arteritis. Arthritis Rheum 2002;47:29-35.
11. Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, et al. Association between strong systemic inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998;41:26-32. (Pubitemid 28041919)
12. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant-cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005;84:269-276 (Pubitemid 41368480)
13. Cid MC, Garcia-Martinez A, Lozano E, Espigol-Frigole G, Hernandez-Rodriguez J. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007;33:819-834 (Pubitemid 350130315)
14. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-708
15. Hayreth SS, Zimmerman B. Visual deterioration in giant-cell arteritis patients while on high doses of glucocorticosteroid therapy. Ophthalmology 2003;110:1204-1215 (Pubitemid 36676655)
16. Cid MC, Prieto-Gonzalez S, Arguis P, Espigol-Frigole G, Butjosa M, Hernandez-Rodriguez J, et al. The spectrum of vascular involvement in giant-cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. APMIS Suppl 2009;127:10-20.
17. Park JL, Jones JG, Hazleman BL. Relationship of the ESR to acute phase proteins in polymyalgia rheumatica and giant-cell arteritis. Ann Rheum Dis 1981;40:493-495
18. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-1294
19. Cid MC, Monteagudo J, Oristrell J, Vilaseca J, Pallares L, Cervera R, et al. Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 1996;55:927-930 (Pubitemid 26426689)
20. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-1048
21. Fauchald P, Ryqvold O, Oytese B. Temporal arteritis and polymyalgia rheumatica. Ann Intern Med 1972;77:845-852
22. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995;122: 502-507
23. Lozano E, Segarra M, Garcia-Martinez A, Hernandez-Rodriguez J, Cid MC. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant-cell arteritis. Ann Rheum Dis 2008;67:1581-1588
24. Lozano E, Corbera-Bellalta M, Espigol-Frigole G, Garcia-Martinez A, Hernandez-Rodriguez J, Cid MC, et al. Proinflammatory functions of vascular smooth muscle cells (VSMC) in giant cell arteritis (GCA) [abstract]. Arthritis Rheum 2008;58 Suppl:S928-9.
25. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, et al. Relationship between interleukin-6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006;33:703-708
26. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-3199 (Pubitemid 27157287)
27. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-2406 (Pubitemid 37542988)
28. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006;144:249-256 (Pubitemid 46768207)
29. Van Leuven SI, Kastelein JJ, D'Cruz DP, Hughes GR, Stroes ES. Atherogenesis in rheumatology. Lupus 2006;15:117-121
30. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125-132 (Pubitemid 46256734)
31. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. Circulation 2005;112:976-983 (Pubitemid 41170265)
32. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. Creactive protein and parenteral history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;25:2243-2251
33. Gonzalez-Juanatey C, Lopez-Diaz MJ, Martin J, Llorca J, Gonzalez-Gay MA. Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 2007;57:1481-1486 (Pubitemid 350308847)
34. Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005;53:33-38
35. Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 2008;26 Suppl:S30-4.
36. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al, for the Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007;146:621-630
37. Lozano E, Segarra M, Garcia-Martinez A, Espigol-Frigole G, Hernandez-Rodriguez J, Cid MC, et al. New therapeutic targets in giant-cell arteritis: considerations based on the current pathogenic model and the availability of new therapeutic targets. Clin Exp Rheumatol 2008;26 Suppl:S141-50.
38. Queralt C, Hernandez-Rodriguez J, Garcia-Martinez A, Esteban MJ, Ros I, Fernandez J, et al. Baseline osteopenia is associated with subsequent bone loss and fractures in glucocorticosteroid-treated patients with giant-cell arteritis (GCA) receiving calcium and vitamin D supplements [abstract]. Arthritis Rheum 2000;43 Suppl:S1793.
39. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticosteroid-induced diabetes mellitus: prevalence and risk factors in primary renal disease. Nephron Clin Pract 2007;105:C54-7. (Pubitemid 46143906)
40. Hellmann DB, Uhlfelder ML, Stone JH, Jenckes MW, Cid MC, Guillevin L, et al. Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis Rheum 2003;49:819-825